Aurinia Pharmaceuticals Inc. (AUPH)

Market Cap	692.08M
Revenue (ttm)	129.00M
Net Income (ttm)	-115.46M
Shares Out	141.86M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	866,513
Open	4.92
Previous Close	4.88
Day's Range	4.82 - 4.99
52-Week Range	4.49 - 24.45
Beta	0.92
Analysts	Buy
Price Target	21.74 (+345.5%)
Earnings Date	Nov 3, 2022

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

• Industry: Biotechnology
• IPO Date: Jan 26, 1999
• CEO: Peter Greenleaf
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: AUPH

Full Company Profile

Financial Performance

In 2021, AUPH's revenue was $45.61 million, a decrease of -9.00% compared to the previous year's $50.12 million. Losses were -$180.97 million, 76.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is 21.74, which is an increase of 345.49% from the latest price.

Price Target

$21.74

(345.49% upside)

Analyst Consensus: Buy

Stock Forecasts